Table 1. Basic Characteristics of Study Subjects.
| Variable | Case Patients | (%) |
|---|---|---|
| Mean (SD) age at recruitment, y | 67.3 (9.80) | |
| Median (range) age at recruitment, y | 67.9 (37.2-83.9) | |
| ≤60 y | 52 | 24.6% |
| >60 y | 159 | 75.4% |
| Gender | ||
| male | 121 | 57.4% |
| female | 90 | 42.6% |
| Race | ||
| white | 196 | 92.9% |
| non-white | 15 | 7.11% |
| Vital Status at end of Follow-up | ||
| alive | 30 | 14.2% |
| dead | 181 | 85.8% |
| SEER Stage | ||
| in situ | 2 | 0.95% |
| localized | 25 | 11.8% |
| regional | 101 | 47.9% |
| distant | 71 | 33.6% |
| unstaged | 11 | 5.21% |
| Radiation Therapy | ||
| yes | 145 | 68.7% |
| no | 59 | 28.0% |
| not known | 7 | 3.32% |
| Surgery | ||
| yes | 66 | 31.3% |
| no | 145 | 68.7% |
| not known | 0 | 0.00% |
| Chemotherapy | ||
| yes | 137 | 64.9% |
| no | 72 | 34.1% |
| not known | 2 | 0.95% |
| 5-FU | ||
| yes | 26 | 12.3% |
| no | 174 | 82.5% |
| not known | 11 | 5.21% |
| Gemcitabine | ||
| yes | 98 | 46.4% |
| no | 101 | 47.9% |
| not known | 12 | 5.69% |
| Erlotinib | ||
| yes | 23 | 10.9% |
| no | 177 | 83.9% |
| not known | 11 | 5.21% |
| Capecitabine | ||
| yes | 20 | 9.48% |
| no | 180 | 85.3% |
| not known | 11 | 5.21% |
| Cisplatin/Oxaliplatin | ||
| yes | 15 | 7.11% |
| no | 185 | 87.7% |
| not known | 11 | 5.21% |